Charles Grassley news from FierceBiotech
NewsALSO NOTED: U.S. hatches $265M regenerative medicine initiative; Merck KGaA budgets €1B for R&D;and much more...
> The U.S. government is creating a $265 million research initiative that will develop new stem cell technology to re-grow the skin, limbs and muscles of soldiers injured in Iraq and Afghanistan. Read more...
Blog divines new FDA standard on data integrity
Drug developers with questionable data beware. The FDA is taking no prisoners, and handing out no approvals, for developers suffering from data integrity issues. That's the world from In Vivo, which Read more...
ALSO NOTED: AstraZeneca may shake up R&D with spin-off; Vertex sells stock; and much more...
> AstraZeneca is considering spinning off its GI research institute into a separate company that would go out into the market and hunt for venture capital backing, according to Swedish newspaper Read more...
ALSO NOTED: Novartis sinks$816.5M into Italian vaccine plant; GSK, Astellas take a pass on Theravance's drugs; and much more...
> Novartis is pledging to sink €600 million ($816.5 million) into new and expanded facilities in Italy. Read more...
| Press ReleasesPRESS RELEASE: Floor Statement of U.S. Senator Chuck Grassley Floor Statement of U.S. Senator Chuck Grassley of Iowa Ranking Member of the Committee on Finance Intimidation of Scientists WASHINGTON, Nov. 16, 2007--Sen. Chuck Grassley has released a floor Read more... |
Get more Charles Grassley coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends